A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

Investigational New Drugs

Volumn 34, Issue 2, 2016, Pages 216-224

  Infante, Jeffrey R ^a   Mendelson, David S ^b   Burris, Howard A ^a   Bendell, Johanna C ^a   Tolcher, Anthony W ^c   Gordon, Michael S ^b   Gillenwater, Heidi H ^d   Arastu Kapur, Shirin ^d   Wong, Hansen L ^d   Papadopoulos, Kyriakos P ^c  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Pinnacle Oncology Hematology   (United States)

^c South Texas Accelerated Research Therapeutics (START)   (United States)

^d ONYX PHARMACEUTICALS   (United States)

Author keywords

Carfilzomib; Dose escalation; Oprozomib; Phase 1; Proteasome inhibitor

Indexed keywords

OPROZOMIB; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANGIOSARCOMA; ANUS CARCINOMA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BREAST CANCER; CARCINOID; CHONDROSARCOMA; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHROCYTE; FATIGUE; FEMALE; FEVER; FIRST IN HUMAN STUDY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HALLUCINATION; HUMAN; HUMAN CELL; HYPONATREMIA; HYPOPHOSPHATEMIA; INSOMNIA; KIDNEY CANCER; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER CANCER; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MELANOMA; MERKEL CELL TUMOR; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVARY CANCER; PANCREAS TUMOR; PELVIS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECTUM CARCINOMA; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERINE CERVIX CANCER; UTERUS CARCINOMA; VOMITING; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; OLIGOPEPTIDES; PROTEASOME INHIBITORS;

EID: 84961051256     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0327-x     Document Type: Article

References (18)

1. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 82:373-428
2. Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417-421
3. Adams J (2004) The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360
4. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617
5. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. (2015) Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). American Society of Hematology Annual Meeting; Orlando, FL; December 5-8. Abstract 727
6. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817-2825
7. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S et al (2007) A phase II study of single agent bortezomib in patients with metastatic breast cancer: A single institution experience. Cancer Invest 25:733-737
8. Papadopoulos KP, Burris HA III, Gordon M, Lee P, Sausvlle EA, Rosen PJ et al (2013) A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 72:861-868
9. Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ et al (2008) Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol 19:946-950
10. Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH et al (2011) A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 29:1475-1481
11. Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G et al (2015) Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs 33:652-663
12. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y et al (2009) Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 52:3028-3038
13. Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF et al (2013) The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 27:430-440
14. Roccaro AM, Sacco A, Aujay M, No HT, Azab AK, Azab F et al (2010) Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 115:4051-4060
15. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B et al (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116:4906-4915
16. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM et al (2012) The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy 8:1873-1874
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubenstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
18. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events, version 4.02 (2009) In: [Internet]. Bethesda, MD: U.S. Department of Health and Human Services. 2013 [cited 2013 June 2]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE-4.02-2009-09-15-QuickReference-8.5x11.pdf